肺炎患者的葡萄糖皮质体剂量-死亡关系:揭示值效应的值
Saibin Wang1,2, Qian Ye3
1Department of Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Jinhua, Zhejiang Province, China.
Frontiers in pharmacology
|October 4, 2024
概括
在肺炎患者中使用葡萄糖皮质醇显示出对死亡风险的值效应. 接受高剂量葡萄糖皮质类药物超过20克甲基普雷迪尼索隆的男性患者需要密切监测,因为死亡风险增加.
科学领域:
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 葡萄糖皮质激素治疗对肺炎患者死亡率的影响还不清楚.
- 这项研究调查了累积葡萄糖皮质激素剂量与肺炎患者死亡率之间的关联.
研究的目的:
- 确定二次性肺炎患者累积葡萄糖皮质激素剂量 (ADG) 和死亡风险之间的关系.
- 为了确定潜在的值效应和影响葡萄糖皮质类药物使用相关的死亡风险的因素.
主要方法:
- 来自DRYAD数据库的数据分析,包括五年来来自六所学术医院的628名肺炎患者.
- 使用零碎线性和多变量回归分析来评估ADG对死亡率的影响,调整混因素.
主要成果:
- 在ADG和死亡风险之间观察到非线性关系.
- 与较低或较高剂量相比,在甲基普雷迪尼索隆20-39克的ADG患者中发现死亡风险明显降低.
- 在男性患者中,超过20g的甲基prednisolone增加了30天和90天死亡风险.
结论:
- 在二次性肺炎的葡萄糖皮质醇使用者中,ADG和死亡率之间存在潜在的值效应.
- 接受高剂量葡萄糖皮质类药物超过20克甲基普雷迪尼索隆的男性患者需要密切监测死亡风险升高.
相关概念视频
Pulmonary Tuberculosis I
221
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
221
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
COPD: Management Using Bronchodilators and Corticosteroids
185
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
185
Hypoglycemia and Glucagon
206
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
206
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
226
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
226


